Equities analysts expect that Cardlytics Inc (NASDAQ:CDLX) will post $37.50 million in sales for the current fiscal quarter, Zacks reports. Four analysts have issued estimates for Cardlytics’ earnings, with estimates ranging from $37.11 million to $37.88 million. The company is expected to issue its next earnings report after the market closes on Tuesday, November 13th.

According to Zacks, analysts expect that Cardlytics will report full year sales of $154.30 million for the current year, with estimates ranging from $153.00 million to $155.74 million. For the next year, analysts forecast that the firm will report sales of $206.85 million, with estimates ranging from $190.00 million to $223.93 million. Zacks’ sales averages are a mean average based on a survey of sell-side analysts that follow Cardlytics.

Cardlytics (NASDAQ:CDLX) last issued its quarterly earnings data on Tuesday, August 14th. The company reported ($0.21) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.53) by $0.32. The company had revenue of $35.57 million for the quarter, compared to the consensus estimate of $34.89 million. The business’s quarterly revenue was up 8.4% on a year-over-year basis.

A number of brokerages recently commented on CDLX. Zacks Investment Research upgraded Cardlytics from a “sell” rating to a “hold” rating in a research note on Tuesday, October 16th. SunTrust Banks restated a “buy” rating and set a $27.00 price objective on shares of Cardlytics in a research note on Tuesday, September 11th. Bank of America restated a “hold” rating and set a $22.00 price objective on shares of Cardlytics in a research note on Friday, August 17th. Finally, KeyCorp lowered their price objective on Cardlytics from $30.00 to $28.00 and set an “overweight” rating for the company in a research note on Wednesday, August 15th. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $24.40.

Shares of CDLX opened at $19.24 on Friday. The firm has a market cap of $402.45 million and a P/E ratio of -2.40. The company has a quick ratio of 2.24, a current ratio of 2.24 and a debt-to-equity ratio of 1.29. Cardlytics has a 12 month low of $11.10 and a 12 month high of $28.29.

In other news, Director Polaris Venture Management Co. sold 150,000 shares of the stock in a transaction on Thursday, September 13th. The stock was sold at an average price of $25.04, for a total value of $3,756,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Lynne Marie Laube sold 1,349 shares of the stock in a transaction on Friday, August 17th. The stock was sold at an average price of $20.66, for a total value of $27,870.34. The disclosure for this sale can be found here. In the last three months, insiders sold 155,194 shares of company stock valued at $3,863,308.

Several large investors have recently added to or reduced their stakes in CDLX. FMR LLC grew its stake in shares of Cardlytics by 68.7% in the third quarter. FMR LLC now owns 3,194,572 shares of the company’s stock worth $79,992,000 after purchasing an additional 1,300,376 shares in the last quarter. Frontier Capital Management Co. LLC lifted its holdings in shares of Cardlytics by 212.7% in the third quarter. Frontier Capital Management Co. LLC now owns 711,629 shares of the company’s stock valued at $17,819,000 after buying an additional 484,044 shares during the period. BlackRock Inc. acquired a new stake in shares of Cardlytics in the first quarter valued at $3,420,000. Millennium Management LLC acquired a new stake in shares of Cardlytics in the first quarter valued at $2,588,000. Finally, Emerald Mutual Fund Advisers Trust lifted its holdings in shares of Cardlytics by 101.6% in the third quarter. Emerald Mutual Fund Advisers Trust now owns 276,355 shares of the company’s stock valued at $6,920,000 after buying an additional 139,262 shares during the period. 49.82% of the stock is owned by institutional investors.

About Cardlytics

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

Featured Story: Bear Market – How and Why They Occur

Get a free copy of the Zacks research report on Cardlytics (CDLX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Cardlytics (NASDAQ:CDLX)

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.